- Home
- CRVO vs XBIT Comparison
CRVO vs XBIT Comparison
Compare CRVO & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- XBIT
- Stock Information
- Founded
- CRVO 2001
- XBIT 2005
- Country
- CRVO United States
- XBIT United States
- Employees
- CRVO N/A
- XBIT N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- XBIT Pharmaceuticals and Biotechnology
- Sector
- CRVO Health Care
- XBIT Health Care
- Exchange
- CRVO Nasdaq
- XBIT Nasdaq
- Market Cap
- CRVO 95.4M
- XBIT 105.2M
- IPO Year
- CRVO N/A
- XBIT 2015
- Fundamental
- Price
- CRVO $9.80
- XBIT $2.94
- Analyst Decision
- CRVO Strong Buy
- XBIT
- Analyst Count
- CRVO 8
- XBIT 0
- Target Price
- CRVO $25.43
- XBIT N/A
- AVG Volume (30 Days)
- CRVO 1.5M
- XBIT 55.6K
- Earning Date
- CRVO 05-13-2025
- XBIT 05-09-2025
- Dividend Yield
- CRVO N/A
- XBIT N/A
- EPS Growth
- CRVO N/A
- XBIT N/A
- EPS
- CRVO N/A
- XBIT N/A
- Revenue
- CRVO $9,737,974.00
- XBIT N/A
- Revenue This Year
- CRVO N/A
- XBIT N/A
- Revenue Next Year
- CRVO N/A
- XBIT N/A
- P/E Ratio
- CRVO N/A
- XBIT N/A
- Revenue Growth
- CRVO 36.29
- XBIT N/A
- 52 Week Low
- CRVO $1.80
- XBIT $2.65
- 52 Week High
- CRVO $25.69
- XBIT $9.45
- Technical
- Relative Strength Index (RSI)
- CRVO 55.40
- XBIT 44.32
- Support Level
- CRVO $9.03
- XBIT $2.77
- Resistance Level
- CRVO $10.89
- XBIT $3.38
- Average True Range (ATR)
- CRVO 1.90
- XBIT 0.33
- MACD
- CRVO -0.29
- XBIT -0.01
- Stochastic Oscillator
- CRVO 32.37
- XBIT 29.90
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.